Skip to main content
    Z

    Zevra Therapeutics Inc. (ZVRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.27
    +0.04 (+0.39%)

    Market Cap: $607.50M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    49%(19/39)
    Avg Surprise
    -5.06%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.18
    Range$0.13 - $0.21
    3 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.22-20.9%
    60d ago$0.19-8.6%
    30d ago$0.19-8.6%
    7d ago$0.19-8.6%
    Current$0.18
    Revenue Consensus
    $37M
    Range$35M - $41M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.73
    Range$0.60 - $0.83
    3 analysts
    Revenue Consensus
    $48M
    Range$45M - $54M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.73---
    Sep 26EST
    		-$0.18---
    Jun 26
    Reported Aug 5
    		$0.25$0.08+212.50%Beat+516.7%
    Mar 26
    Reported May 6
    		$0.18$0.08+125.00%Beat+400.0%
    Dec 25
    Reported Mar 9
    		$0.19$0.05+280.00%Beat+127.5%
    Sep 25
    Reported Nov 5
    		$-0.01N/A+75.00%Beat+98.6%
    Jun 25
    Reported Aug 12
    		$-0.06N/A-104.35%Miss+87.5%
    Mar 25
    Reported May 13
    		$-0.06N/A+66.67%Beat+85.0%
    Dec 24
    Reported Mar 11
    		$-0.69$-0.40-73.11%Miss-72.5%
    Sep 24
    Reported Nov 12
    		$-0.69$-0.41-68.29%Miss-72.5%
    Jun 24
    Reported Aug 13
    		$-0.48$-0.44-9.09%Miss-220.0%
    Mar 24
    Reported May 8
    		$-0.40$-0.48+16.67%Beat-17.6%
    Dec 23
    Reported Mar 28
    		$-0.40$-0.27-48.15%Miss-53.8%
    Sep 23
    Reported Nov 7
    		$-0.40$-0.30-33.33%Miss-110.5%
    Jun 23
    Reported Aug 14
    		$-0.15N/A+55.88%Beat+78.6%
    Mar 23
    Reported May 15
    		$-0.34$-0.23-47.83%Miss-580.0%
    Dec 22
    Reported Mar 7
    		$-0.26$-0.17-52.94%Miss-225.0%
    Sep 22
    Reported Nov 9
    		$-0.19$-0.10-90.00%Miss-280.0%
    Jun 22
    Reported Aug 11
    		$-0.70$-0.14-400.00%Miss-75.0%
    Mar 22
    Reported May 12
    		$-0.05$-0.05+0.00%Beat+96.9%
    Dec 21
    Reported Mar 30
    		$-0.08$-0.07-14.29%Miss+92.5%
    Sep 21
    Reported Nov 10
    		$-0.05$-0.08+37.50%Beat+92.2%
    Jun 21
    Reported Aug 12
    		$-0.40$0.23-273.91%Miss-350.0%
    Mar 21
    Reported May 13
    		$-1.61$-0.17-847.06%Miss+16.1%
    Dec 20
    Reported Mar 11
    		$-1.07$-0.64-67.19%Miss-568.8%
    Sep 20
    Reported Oct 29
    		$-0.64$-0.80+20.00%Beat-166.7%
    Jun 20
    Reported Aug 12
    		$0.16$-0.02+900.00%Beat+103.0%
    Mar 20
    Reported May 12
    		$-1.92$-1.76-9.09%Miss+73.9%
    Dec 19
    Reported Feb 28
    		$-0.16N/A+88.24%Beat+95.0%
    Sep 19
    Reported Nov 14
    		$0.96N/A+121.43%Beat+107.2%
    Jun 19
    Reported Aug 13
    		$-5.28$-6.80+22.35%Beat+49.2%
    Mar 19
    Reported May 14
    		$-7.36$-7.36+0.00%Beat+74.0%
    Dec 18
    Reported Feb 28
    		$-3.20N/A+57.89%Beat+72.2%
    Sep 18
    Reported Nov 8
    		$-13.41$-12.32-8.85%Miss-23.3%
    Jun 18
    Reported Aug 9
    		$-10.40$-15.42+32.56%Beat-47.7%
    Mar 18
    Reported May 10
    		$-28.32$-11.04-156.52%Miss-110.7%
    Dec 17
    Reported Mar 29
    		$-11.52$-10.96-5.11%Miss-5.9%
    Sep 17
    Reported Nov 9
    		$-10.88$-10.76-1.12%Miss-
    Jun 17
    Reported Aug 10
    		$-7.04$-10.08+30.16%Beat-
    Mar 17
    Reported May 10
    		$-13.44$-10.24-31.25%Miss-
    Dec 16
    Reported Mar 9
    		$-10.88$-11.15+2.42%Beat-

    Key Metrics

    Valuation
    P/E Ratio16.84EV/EBITDA7.03x
    Price/FCF18.66xFCF Yield5.36%
    Profitability
    Profit Margin42.80%Operating Margin42.30%
    ROE34.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-39.45x
    Current Ratio5.17xQuick Ratio5.12x
    Trading Statistics
    Beta0.98Avg Volume951.10K
    52-Week High$15.0452-Week Low$8.01

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.71
    SMA 20$10.97
    SMA 50$11.49
    SMA 200$10.66
    EMA 10$10.71
    EMA 20$10.96
    EMA 50$11.31
    EMA 200$10.86

    MACD

    Line: -0.30Signal: -0.25Hist: -0.05

    ADX

    ADX: 15.5+DI: 19.7-DI: 29.3

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down64.0
    PSAR$11.43

    Bollinger Bands

    Upper Band$12.01
    Lower Band$9.93
    %B Position1895%(Upper)
    Band Width0.16

    RSI (14-Day)

    Neutral
    38.5

    Momentum Oscillators

    Stoch %K27.3
    Stoch %D46.3
    Williams %R-74.3
    ROC (10d)0.9%
    Momentum0.09
    CCI (20d)-105.4
    MFI (14d)50.2

    Volatility Measures

    ATR (14d)$0.50(4.9%)
    StdDev (20d)0.52
    Hist Vol54.2%(High)

    Volume Flow

    VWAP$10.36
    OBV37.6M
    AD Line15.5M
    CMF (20d)-0.153

    Volume Metrics

    Avg Vol (20d)926.9K
    Vol Ratio0.5x(Low)
    VWMA (20d)$10.94

    Pivot Points

    R3$11.05
    R2$10.82
    R1$10.53
    Pivot Point$10.30
    S1$10.01
    S2$9.78
    S3$9.49

    Advanced Oscillators

    TSI-16.11
    Ultimate Osc43.6
    KST-87.87

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$39.66M$36.22M$34.13M$26.06M$25.88M$20.40M$12.04M$3.69M$4.45M$3.42M$12.92M$2.90M
    Cost of Revenue$0$1.90M$1.52M$1.24M$0$1.34M$1.37M$2.30M$3.57M$175,000$1.23M$144,000
    Gross Profit$39.66M$34.32M$32.60M$24.82M$25.88M$19.06M$10.68M$1.39M$876,000$3.25M$11.69M$2.75M
    Operating Expenses$22.89M$-17,823,000$23.29M$20.68M$96.92M$24.42M$26.09M$28.70M$24.67M$23.74M$26.85M$18.11M
    R&D$4.49M$4.39M$2.62M$3.43M$3.43M$3.26M$8.35M$10.95M$10.52M$12.28M$11.42M$12.30M
    SG&A$16.56M$20.78M$20.35M$16.93M$20.78M$19.55M$16.13M$16.21M$12.60M$9.93M$14.66M$5.82M
    Operating Income$16.78M$52.15M$9.31M$4.14M$-71,039,000$-5,362,000$-15,416,000$-27,306,000$-23,795,000$-20,486,000$-15,157,000$-15,364,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-2,565,000$878,000$236,000$-262,000$-369,000$1.43M$2.27M$1.26M$1.84M$-194,000$548,000$-1,372,000
    Income Before Tax$12.79M$44.80M$12.67M$-977,000$76.91M$-1,917,000$-20,368,000$-33,225,000$-19,855,000$-16,692,000$-19,892,000$-10,190,000
    Income Tax Expense$4.04M$6.91M$501,000$-433,000$2.20M$1.18M$15.37M$0$70,000$-70,000$0$177,000
    Net Income$8.75M$37.89M$12.16M$-544,000$74.71M$-3,099,000$-35,739,000$-33,225,000$-19,925,000$-16,622,000$-19,892,000$-10,367,000
    EBITDA$10.00M$45.43M$12.41M$-2,058,000$77.43M$853,000$-17,343,000$-30,345,000$-16,453,000$-15,324,000$-18,557,000$-11,500,000
    EBIT$10.23M$45.68M$12.90M$-1,239,000$76.54M$-491,000$-18,101,000$-31,962,000$-18,015,000$-16,886,000$-19,344,000$-11,562,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ZVRA

    News

    Form 4 Zevra Therapeutics Inc: Neil F. McFarlane (Director, President and CEO) For: 10 October

    This article reports on a Form 4 filing for Zevra Therapeutics Inc., indicating a transaction by Neil F. McFarlane, who holds the titles of Director, President...

    Investing.com Nigeria•10/14/26•Neutral

    Form 4 Zevra Therapeutics Inc: Neil F. McFarlane (Director, President and CEO) For: 10 October

    This article reports on a Form 4 filing for Zevra Therapeutics Inc., indicating a transaction by Neil F. McFarlane, who holds the positions of Director, President...

    Investing.com Canada•10/14/26•Neutral

    Zevra Therapeutics president and CEO sells $224,948 in stock By Investing.com

    The President and CEO of Zevra Therapeutics (NASDAQ:ZVRA), Neil F. McFarlane, sold 20,000 shares of the company's common stock for a total of $224,948 on October 12, 2026. This sale...

    Investing.com Canada•10/14/26•Neutral

    A 20,000-share sale was reported by Zevra Therapeutics (ZVRA) director Neil F. McFarlane.

    Zevra Therapeutics (ZVRA) director and officer Neil F. McFarlane reported selling 20,000 common shares on October 12, 2026, for an aggregate market value of $227,800. This sale was reported via a Form 144 filing...

    Stock Titan•10/13/26•Neutral

    Zevra Therapeutics, Inc. (ZVRA) options chain

    This page displays the options chain for Zevra Therapeutics, Inc. (ZVRA), showing real-time price data and basic company stock information. As of the data presented...

    Yahoo Finance UK•10/10/26•Neutral

    ZVRA Valuation and Fair Value

    P/E
    16.8x
    Forward P/E
    10.7x
    EV/EBITDA
    7.0x
    P/FCF
    18.7x
    PEG
    10.7x
    P/B
    2.8x
    See GNG's fair value

    ZVRA Profitability: Margins, ROIC and FCF

    Gross margin
    96.6%
    Operating margin
    42.3%
    Net margin
    42.8%
    ROE
    34.8%
    FCF margin
    23.9%
    FCF yield
    5.4%

    ZVRA Competitors

    CompanyTicker
    SurModics IncSRDX
    ProKidney Corp.PROK
    Pacific Biosciences of CaliforniaPACB
    Sophia Genetics SASOPH
    Performant Healthcare, IncPHLT
    Phathom Pharmaceuticals IncPHAT
    Avalo Therapeutics IncAVTX
    Olema Pharmaceuticals IncOLMA

    Sector: Healthcare

    ZVRA Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    2
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    ZVRA Bull Case vs Bear Case

    Bull case

    • ZVRA converts 23.9% of revenue into free cash flow.
    • ZVRA has a 42.8% net profit margin.
    • ZVRA grew quarterly revenue 53.3% year over year.

    ZVRA Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    64.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.18
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About ZVRA

    Does ZVRA pay dividends?

    Zevra Therapeutics Inc. (ZVRA) does not currently pay a regular dividend.

    What is ZVRA's P/E ratio?

    Zevra Therapeutics Inc. has a price-to-earnings (P/E) ratio of 16.84.

    What is ZVRA's market cap?

    Zevra Therapeutics Inc. (ZVRA) has a market capitalization of $607.50M with a current stock price of $10.27.

    Related stocks

    Sector: Healthcare

    All stocks starting with Z

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In